论文部分内容阅读
1967年以来,法国Roux研究从羊种布氏菌中提取酚不溶性抗原组分(以下简称PI),初用于人群免疫,后用于临床脱敏治疗布氏菌病(以下简称布病),取得良好效果。我们继1983年卫生部批准长春生物制品研究所参照Roux的方法从牛型104M布氏菌中提取的PI进行中量人群免疫反应观察之后,在国内首次应用PI治疗了慢性布病,现将30例住院病人的临床观察结果报告如下: 本组病例大多来自黑龙江省内农牧场,按地方病北办1977年制订的人布鲁氏菌病诊断和治疗效果判定试行标准,确诊
Since 1967, the French Roux study extracted phenolic insoluble antigen components (hereinafter referred to as PI) from sheep Brevibacterium breve and was initially used for population immunization and then used for clinical desensitization treatment of brucellosis (hereinafter referred to as brucellosis) Achieve good results. We follow the 1983 Ministry of Health approved the Changchun Institute of Biological Products in accordance with the Roux method extracted from the bovine 104M Brevibacterium PI quantitative immune response observed in the country for the first time using PI treatment of chronic brucellosis, now 30 Cases of inpatient clinical observations are as follows: Most of the patients in this group came from farms in Heilongjiang Province, according to endemic diseases in northern Hebei established in 1977, the diagnosis and treatment of brucellosis diagnosis and treatment trial criteria, diagnosis